IDH1 and central nervous system cancer: TET2 mutations in various myeloid cancer [14, 15], or mutations of IDH1 and IDH2 in low-grade gliomas, which can inhibit DNA hydroxymethylation by TET enzymes [19-22, 28], have been reported and cause DNA hypermethylation phenotype.